About Us
Mission
Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow to tissues. Particularly for diabetic patients at high risk for limb amputation and associated morbidity. The company’s lead program is an induced-pluripotent stem cell (iPSC)-derived vasculogenic cell with the potential to forge new blood vessels in oxygen-starved tissues.
History
Vascugen launched in 2018 in partnership with Indiana University (IU), a leading institution for medical research. Our mission is to develop advanced medicines for life-threatening conditions which result from insufficient microvascular circulation. These conditions often arise as a complication of diabetes or arterial disease. Afflicted patients lack treatment options and are at high risk for major amputations and death. We are advancing a potent cell replacement therapy designed to form microvascular structures and thereby restore circulation.
2018-11-16 - IU Philanthropic Venture Fund Invests in Regenerative Medicine Company Vascugen
Technology
Vascugen has exclusive rights from Indiana University (IU) to a broad technology portfolio developed in the laboratory of our scientific founder, Mervin C. Yoder, MD. Our goal is to advance an allogeneic, donor-independent cell replacement therapy that is directly capable of microvascular regeneration. To achieve this, we have established partnerships that provide access to two Nobel Prize winning technologies, induced pluripotent stem cells (iPSCs) & gene modification.
2018-05-01 - Vascugen Licenses Stem Cell Technology for Blood Vessel Regeneration Developed at IU School of Medicine
Manufacturing
Vascugen utilizes an integrated approach to advance therapeutic candidates from early R&D through to clinical (cGMP) manufacturing. By doing so we mitigate technology and tech transfer risks along the development chain. Embedded within our R&D facility is a state-of-the-art cleanroom designed to iPSC industry standards. Dedicated quality assurance (QA) and a quality management system (eQMS) are in place for compliance and product release. Where feasible, we deploy closed system manufacturing platforms in our processes.
